Hepatitis C Main Section
FDA-approved Monotherapies
FDA-approved Combination Therapies
Intron A
Roferon
Infergen
Pegasys
PEG-Intron
Pegasys + Copegus
PEG-Intron + Rebetol
Intron A + Rebetol
Roferon A + Ribavirin
Link to Hepatitis C Main Section
HCV - Standard Interferon Therapy
Intron A
(Recombinant Interferon Alfa-2b)
Roferon A
(Recombinant Interferon Alfa-2a)
Infergen
(consensus interferon/interferon alfacon-1)


Intron A - (Recombinant Interferon Alfa-2b) MONOTHERAPY
Intron A Drug Summary
(Monotherapy)

HCV Genotypes 2 and 3 Do Not Respond the Same to Interferon-based Treatment - 1/29/08

Interferon-based Therapy Lowers Lymphoma Risk in Hepatitis C Patients - 1/25/08

Growth Hormone Deficiency Common in Hepatitis C Patients, but Improves with Interferon-based Treatment - 1/08/08

Eltrombopag Raises Platelet Counts, Enabling Initiation of Interferon-based Therapy for Hepatitis C - 12/14/07

Factors That Affect Success of Interferon-based Treatment for Hepatitis C    - 7/17/07

Statins Improve Sustained Response to Interferon-based Therapy in Small Study - 5/25/07

Sustained Response to Interferon Monotherapy Reduces Rates of Liver Cancer and Death in Patients with HCV-related Cirrhosis  - 3/27/07

Study Confirms Poorer Interferon Treatment Response in African Americans   - 8/25/06

Treatment of Patients with Advanced Hepatitis C with a Low Accelerating Dosage Regimen of Peginterferon/Ribavirin Can Result in Favorable Clinical  Outcomes - 9/21/05




Roferon A - (Recombinant Interferon Alfa-2a) MONOTHERAPY

HCV Genotypes 2 and 3 Do Not Respond the Same to Interferon-based Treatment - 1/29/08

Interferon-based Therapy Lowers Lymphoma Risk in Hepatitis C Patients - 1/25/08

Growth Hormone Deficiency Common in Hepatitis C Patients, but Improves with Interferon-based Treatment - 1/08/08

Eltrombopag Raises Platelet Counts, Enabling Initiation of Interferon-based Therapy for Hepatitis C - 12/14/07

Factors That Affect Success of Interferon-based Treatment for Hepatitis C    - 7/17/07

Statins Improve Sustained Response to Interferon-based Therapy in Small Study - 5/25/07

Sustained Response to Interferon Monotherapy Reduces Rates of Liver Cancer and Death in Patients with HCV-related Cirrhosis  - 3/27/07

Study Confirms Poorer Interferon Treatment Response in African Americans   - 8/25/06

Response to Interferon Alfa Therapy in a Patient with HCV-related Arthritis - 7/13/05

Interferon Gamma Has No Effect on HCV RNA Levels in Relapsers and Nonresponders to Interferon Alfa-based Regimens - 6/24/05





Infergen (consensus interferon;interferon alfacon-1) MONOTHERAPY

Infergen Drug Summary
Monotherapy

Interferon-based Therapy Lowers Lymphoma Risk in Hepatitis C Patients - 1/25/08

HCV Genotypes 2 and 3 Do Not Respond the Same to Interferon-based Treatment - 1/29/08

Interferon-based Therapy Lowers Lymphoma Risk in Hepatitis C Patients - 1/25/08

Statins Improve Sustained Response to Interferon-based Therapy in Small Study - 5/25/07

Promising Data on Consensus Interferon Retreatment of Relapsers and Non-Responders - 6/09/06

Valeant Pharmaceuticals to Acquire Consensus Interferon (Infergen) from Intermune - 11/30/05

Sustained Virologic Response Rates from a Randomized Trial of HCV Genotype-1 Subjects Treated with Either Consensus IFN and Ribavirin or Pegylated Interferon alfa-2b and Ribavirin - 11/30/05

Consensus Interferon (Infergen) and Ribavirin in Nonresponders to Prior Therapy with Either Standard Interferon Alfa and Ribavirin or Pegylated Interferon and Ribavirin - 11/30/05